ANKRD18B

Across TCGA pan-cancer cohorts, ANKRD18B Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ANKRD18B data layer compared with 27 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher ANKRD18B Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ANKRD18B expression acts as an unfavorable survival marker.

LIHC, READ, and ESCA are the cancer types where ANKRD18B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	All	0.054	0.779	<.001	30	view →
READ	DFS	Median	All	0.182	0.819	.004	18	view →
ESCA	DFS	Median	All	0.045	0.533	<.001	12	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
SARC	DFS	Median	All	0.124	0.595	.005	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ANKRD18B–LIHC (OS)

Open the LIHC breakdown →